Lisaftoclax (APG-2575): In CLL/SLL Treatment: Safety and Efficacy as Monotherapy or Combined with Acalabrutinib or Rituximab Matthew Davids MD - Synopsis below extracted from the video transcript.
Acalabrutinib (AVO): A Promising New Triplet Treatment Option for High-Risk CLL Patients Phase 2 Study Results Matthew Davids MD - Synopsis below extracted from the video transcript.
Allogeneic Hematopoietic Cell Transplantation: Relapsed or Refractory AML Phase 3 ASAP Trial Johannes Schetelig - Synopsis below extracted from the video transcript.
Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD - Synopsis below extracted from the video transcript.
Odronextamab: Promising Results in Treating Relapsed/Refractory Follicular Lymphoma: Findings from Phase II Study ELM-2 Tae Min Kim MD - Synopsis below extracted from the video transcript.
REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD - Synopsis below extracted from the video transcript.
Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Dr. Mobasher - Synopsis below extracted from the video transcript.
